หน้าแรก
ค้นหา
Dr. Kopetz on the Importance of Molecular Testing in CRC
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Kopetz on the Importance of Molecular Testing in CRC
The Importance of Molecular Testing in CRC
Dr. Kopetz on the Significance of Tumor Sidedness in CRC
Molecular Testing and Tumor Sidedness in CRC
Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC
Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC
Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC
What is the future role of ctDNA as a biomarker in colorectal cancer?
Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients
Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy
Importance of HER2 Expression in CRC
Impact of molecular subsets in colorectal cancer on adjuvant and advanced disease therapy
The Role of Biomarkers in Colorectal Cancer
Prof Eric Van Cutsem, MD & Scott Kopetz, MD discuss Colorectal Cancer: https://bit.ly/3vfphKP
